دورية أكاديمية

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

التفاصيل البيبلوغرافية
العنوان: Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
المؤلفون: Blair McNamara, Stefania Bellone, Cem Demirkiran, Tobias Max Philipp Hartwich, Alessandro D. Santin
المصدر: Gynecologic Oncology Reports, Vol 48, Iss , Pp 101218- (2023)
بيانات النشر: Elsevier, 2023.
سنة النشر: 2023
المجموعة: LCC:Gynecology and obstetrics
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Lenvatinib, Pembrolizumab, Clear Cell Ovarian cancer, Recurrent, Treatment-resistant, Gynecology and obstetrics, RG1-991, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Background: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. Case: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles. Conclusion: The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2352-5789
Relation: http://www.sciencedirect.com/science/article/pii/S2352578923000875; https://doaj.org/toc/2352-5789
DOI: 10.1016/j.gore.2023.101218
URL الوصول: https://doaj.org/article/d7d8924ecf584037b3530fc91d3acc9d
رقم الأكسشن: edsdoj.7d8924ecf584037b3530fc91d3acc9d
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:23525789
DOI:10.1016/j.gore.2023.101218